Two Constructed Antibody-Derived Delivery Vehicles for Targeting Oligodeoxynucleotides to Prostate Tumors Expressing Prostate Specific Antigen

REFERENCES

• Bennett C. F., Chiang M. Y., Chan H., Shoemaker J. E., Mirabelli C. K.. 1992. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol.. 41: 1023–1033. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bera T. K., Viner J., Brinkmann E., Pastan I.. 1999. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Cancer Res.. 59: 4018–4022. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bergan R., Connel Y., Fahmy B., Neckers L.. 1993. Electroporation enhances c-myc antisense oligonucleotide efficacy. Nucleic Acids Res.. 21: 3567–3573. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Brennan M., Davison P. F., Paulus H.. 1985. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science. 229: 81–83. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Corvalan J. R. F., Smith W., Gore V. A.. 1988. Tumor therapy with vinca alkaloids targeted by a hybrid-hybrid monoclonal antibody recognizing both CEA and vinca alkaloids. Int. J. Cancer. 2(S): 22–25
   Google Scholar
• Diamond S. M., Fair W. R., Heston W. D. W.. 1995. Modulation of prostate-specific membrane antigen (PSM) expression in vitro by cytokines and growth factors. Proc. Am. Assoc. Cancer Res.. 36: 643a
   Google Scholar
• Elgamal A. A., Troychak M. J., Murphy G. P.. 1998. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate. 37: 261–269. [CROSSREF], [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Gewirtz A. M., Glazer P. M.. 1996. Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Proc. Natl. Acad. Sci. USA. 93: 3161–3163. [CROSSREF], [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ghetie V., Vitetta E.. 1994. Immunotoxins in the therapy of cancer: from bench to clinic. Pharmac. Ther.. 63: 209–234. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Horoszewich J. S., Kawinski E., Murphy G. P.. 1987. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res.. 7: 927–936
   PubMed Web of Science ®Google Scholar
• Israeli R. S., Powell C. T., Corr J. G., Fair W. R., Heston W. D. W.. 1994. Expression of the prostate-specific membrane antigen. Cancer Res.. 54: 1807–1811. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kang S. H., Zirbes E. L., Kole R.. 1999. Delivery of antisense oligonucleotides and plasmid DNA with various carrier agents. Antisense Nucleic Acid Drug Dev.. 9: 497–505. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Khan D., Williams R. D., Manyak M. J., Haseman M. K., Seldin D. W., Libertino J. A., Maguire R. T.. 1998. 111-indium capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The Prosta Scint Study Group. J. Urology. 159: 2041–2046. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Leonetti J. P., Machy P., Degols G., Lebleu B., Leserman L.. 1990. Antibody-targeted liposomes containing oligodeoxynucleotides complementary to viral RNA selectively inhibit viral replication. Proc. Natl. Acad. Sci. USA. 87: 2448–2451. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Liu H., Rajasekaran A. K., Moy P., Xia Y., Kim S., Navarro V., Rahmati R., Bander N. H.. 1998. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res.. 58: 4055–4060. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Nolan O., O'Kennedy R.. 1990. Bifunctional antibodies: concept, production and applications. Biochim. Biophys. Acta. 1040: 1–11. [CROSSREF], [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Petronis J. D., Regan F., Lin K.. 1998. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin. Nucl. Med.. 23: 672–677. [CROSSREF], [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Pinto J. T., Heston W. D. W.. 1999. Prostate specific membrane antigen, a unique glutamate carboxypeptidase: a review of recent findings. Prostate. 1: 15–26
   Google Scholar
• Rubenstein M., Mirochnik Y., Guinan P.. 1997. Delivery of biotinylated agents to prostate cancer cells utilizing hybrid monoclonal antibodies. In Oligonucleotide and Gene Therapy-Based Antisense Therapeutics with New Applications to Genomics, W., Hori. IBC Library Series, Southborough, MA, 4.2.1–4.2.10
   Google Scholar
• Sinha A. A., Sackrison J. L., DeLeon O. F., Wilson M. J., Gleason D. F.. 1996. Antibody Immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis. Anat. Rec.. 245: 652–661. [CROSSREF], [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Walker I., Irwin W. J., Akhtar S.. 1995. Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharmaceut. Res.. 12: 1548–1553. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Webb K. S., Ware J. L., Parks S. F., Walther P. J., Paulson D. F.. 1985. Evidence for a novel hybrid immunotoxin recognizing ricin A-chain by one antigen-combining site and a prostate restricted antigen by the remaining antigen-combining site: potential for immunotherapy. Cancer. Treat. Rev.. 69: 663–672
   Google Scholar
• Wright G. L., Jr., Haley C., Beckett M. L., Schellhammer P. F.. 1995. Expression of prostate specific membrane antigen in normal, benign and malignant prostate tissues. Urol. Oncol.. 1: 18–28. [CROSSREF]
   PubMedGoogle Scholar